D.E. Shaw & Co
CELL

D.E. Shaw & Co’s PhenomeX Inc. Common Stock CELL Stock Holding History

D.E. Shaw & Co’s Portfolio CELL Stock Details CELL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-148,923
Closed -$149K – 4790
2023
Q3 		$149K Sell
148,923
-667,179
-82% -$511K ﹤0.01% 3808
2023
Q2 		$400K Sell
816,102
-204,893
-20% -$168K ﹤0.01% 3506
2023
Q1 		$1.18M Sell
1,020,995
-64,603
-6% -$118K ﹤0.01% 3050
2022
Q4 		$2.91M Buy
1,085,598
+912,726
+528% +$2.41M ﹤0.01% 2617
2022
Q3 		$494K Sell
172,872
-29,231
-14% -$124K ﹤0.01% 4049
2022
Q2 		$1M Sell
202,103
-170,206
-46% -$892K ﹤0.01% 3637
2022
Q1 		$2.65M Buy
+372,309
New +$3.08M ﹤0.01% 3024
2021
Q1 		– Sell
-14,677
Closed -$1.31M – 4583
2020
Q4 		$1.31M Buy
+14,677
New +$1.23M ﹤0.01% 2850

D.E. Shaw & Co's CELL Position: Q4 2023 in Review

D.E. Shaw & Co sold out of PhenomeX Inc. Common Stock (CELL) in Q4 2023, closing a stake of 148,923 shares — an estimated $149K sold.

D.E. Shaw & Co first reported a position in CELL in Q4 2020 and held it in 8 quarters. The position peaked at $2.91M in Q4 2022. 0 funds tracked by Wall St. Rank hold CELL as of Q4 2023.

  • D.E. Shaw & Co reported no remaining PhenomeX Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 148,923 PhenomeX Inc. Common Stock shares in Q4 2023, an estimated $149K.
  • D.E. Shaw & Co first reported a position in PhenomeX Inc. Common Stock in Q4 2020 and held it in 8 quarters.
  • D.E. Shaw & Co's PhenomeX Inc. Common Stock position peaked at $2.91M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q4 2023.

Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.